60 results on '"Früh M"'
Search Results
2. MA11.09 SAKK 16/18: Neoadjuvant Chemotherapy, Durvalumab and Immune-Modulatory RT in Stage III(N2) NSCLC. Surgical Interim Analysis
3. Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14
4. Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study
5. Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis
6. Corrigendum to ‘Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials’
7. 32P Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis
8. Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
9. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
10. VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial
11. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
12. 557P Binimetinib, pemetrexed (Pem) and cisplatin (Cis), followed by maintenance of Binimetinib and Pem in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations: The phase Ib SAKK 19/16 trial
13. 1237MO SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial
14. Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) – A decision-making analysis amongst European lung cancer experts
15. Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts
16. Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)
17. P2.12-21 Outcomes with Immune Checkpoint Inhibitors (ICI) for Relapsed Small Cell Lung Cancer (SCLC) in a Swiss Cohort
18. EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer
19. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
20. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study
21. Strategien zur Überwindung der erworbenen EGFR-TKI-Resistenz durch T790M spezifische Substanzen am Beispiel von Osimertinib
22. MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry
23. Patterns of recurrence to Osimertinib in T790m positive NSCLC: A Swiss cohort study
24. Evolution and clinical impact of EGFR mutations in circulating free DNA in the BELIEF trial
25. P2.07-012 Patterns of Response to Nivolumab in Patients with Non-Small Cell Lung Cancer (NSCLC)
26. MA 15.11 CCNE1, PTGS2, TGFA and WISP2 Predict Benefit from Bevacizumab and Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer (SAKK19/09)
27. Prognostic impact of drug interactions in patients with advanced cancer
28. Chemotherapy in advanced cancer patients with poor performance status (PS) initiated in an integrated oncology and palliative care (PC) setting: an observational comparative study
29. Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices
30. Targeted therapy for patients with ALK positive NSCLC: Results from the transalpine cohort
31. Afatinib for patients with advanced NSCLC pretreated with chemotherapy and an EGFR tyrosine kinase inhibitor: Retrospective analysis of the Swiss Afatinib Named Patient Program
32. Abstract B072: Phase Ib trial of the RNActive cancer vaccine BI 1361849 (CV9202) and local radiotherapy in patients with stage IV non-small cell lung cancer (NSCLC) with disease control after first-line chemotherapy or during therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: Updated clinical results and immune responses
33. Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial
34. Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study
35. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort
36. 2807 Phase II explorative trial to prospectively investigate predictive molecular biomarkers for efficacy of panitumumab (P) in platinum-pretreated head and neck squamous cell cancer (HNSCC)
37. 2861 Prospective multicenter phase II study of the anti-EGFR (epidermal growth factor receptor) antibody panitumumab (P) in patients with platinum pre-treated, advanced head and neck squamous cell cancer (HNSCC)
38. 3BA A phase II trial of erlotinib (E) and bevacizumab (B) in patients with advanced non-small-cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations with and without T790M mutation. The Spanish Lung Cancer Group (SLCG) and the European Thoracic Oncology Platform (ETOP) BELIEF trial
39. Targeted Therapy for Braf-Mutant Lung Cancer: Results from the European Euraf Cohort Study
40. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma
41. Final Results of the Sakk 16/00 Trial: a Randomized Phase III Trial Comparing Neoadjuvant Chemoradiation to Chemotherapy Alone in Stage Iiia/N2 Non-Small Cell Lung Cancer (Nsclc)
42. Neoadjuvant Chemotherapy and Extrapleural Pneumonectomy (Epp) of Malignant Pleural Mesothelioma (Mpm) with or Without Hemithoracic Radiotherapy: Final Results of the Randomized Multicenter Phase Ii Trial Sakk17/04
43. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)
44. Diffuse large B-cell lymphoma in elderly patients: A retrospective analysis
45. Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib
46. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
47. Tobacco-related cancer mortality: projections for different geographical regions in Switzerland
48. 80P MANAGEMENT OF ELDERLY PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: A SINGLE CENTRE EXPERIENCE
49. Management of Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Single-Center Experience
50. Molecular oncology in lung cancer – between biomarkers and clinical application. Relevance of the Ras–Raf–MEK–ERK pathway
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.